CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.299
EU - Europa 1.982
AS - Asia 1.820
SA - Sud America 288
AF - Africa 51
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 6.475
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.234
RU - Federazione Russa 905
SG - Singapore 693
CN - Cina 543
GB - Regno Unito 289
BR - Brasile 238
IT - Italia 201
HK - Hong Kong 182
VN - Vietnam 163
DE - Germania 124
SE - Svezia 111
FR - Francia 110
IE - Irlanda 93
KR - Corea 57
IN - India 42
FI - Finlandia 38
CA - Canada 37
AU - Australia 30
PL - Polonia 24
MX - Messico 20
ID - Indonesia 19
TR - Turchia 19
AR - Argentina 18
JP - Giappone 16
NL - Olanda 16
UA - Ucraina 16
BD - Bangladesh 15
IQ - Iraq 13
CO - Colombia 10
ZA - Sudafrica 9
AT - Austria 8
BE - Belgio 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
DZ - Algeria 6
NG - Nigeria 6
PH - Filippine 6
TN - Tunisia 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CG - Congo 5
CL - Cile 5
ES - Italia 5
MA - Marocco 5
PK - Pakistan 5
TG - Togo 5
JO - Giordania 4
LT - Lituania 4
PE - Perù 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EC - Ecuador 3
EU - Europa 3
KE - Kenya 3
LV - Lettonia 3
MY - Malesia 3
RO - Romania 3
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
GR - Grecia 2
NO - Norvegia 2
NP - Nepal 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MM - Myanmar 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SM - San Marino 1
TH - Thailandia 1
Totale 6.474
Salva come PNG Salva come JPEG
Città #
Singapore 354
Ashburn 301
Chandler 293
Moscow 288
San Jose 247
Dallas 230
Southend 229
Hong Kong 180
Beijing 146
Dublin 93
The Dalles 86
Woodbridge 83
Verona 75
New York 51
Ho Chi Minh City 49
Ann Arbor 48
Los Angeles 48
Wilmington 41
Lawrence 40
Princeton 40
Jinan 34
Shenyang 34
Hanoi 31
Jacksonville 30
São Paulo 27
Sindelfingen 26
Nanjing 25
Council Bluffs 24
Columbus 23
Perth 23
Munich 22
Buffalo 20
Redondo Beach 19
Warsaw 18
Montreal 17
Santa Clara 16
Tokyo 16
Tianjin 15
Chennai 14
Helsinki 14
Nuremberg 14
Orem 14
Phoenix 14
Falls Church 13
San Francisco 13
Zhengzhou 13
Hebei 12
London 12
Taiyuan 12
Poplar 11
Changsha 10
Houston 10
Redmond 10
Seoul 10
Atlanta 9
Bologna 9
Dong Ket 9
Guangzhou 9
Jakarta 9
Nanchang 9
Redwood City 9
Rome 9
Toronto 9
Belo Horizonte 8
Mexico City 8
Rio de Janeiro 8
Seattle 8
Stockholm 8
Brussels 7
Denver 7
Frankfurt am Main 7
Milan 7
Norwalk 7
Porto Alegre 7
Taizhou 7
Tashkent 7
Thái Nguyên 7
Ankara 6
Chengdu 6
Haikou 6
Haiphong 6
Kent 6
Kyiv 6
New Delhi 6
Ningbo 6
Querétaro 6
Abuja 5
Amsterdam 5
Basingstoke 5
Brasília 5
Chicago 5
City of London 5
Da Nang 5
Düsseldorf 5
Falkenstein 5
Johannesburg 5
Lomé 5
Shanghai 5
Washington 5
Bergamo 4
Totale 3.845
Salva come PNG Salva come JPEG
Nome #
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 243
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 243
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 215
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 200
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 196
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 194
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 183
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 182
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 181
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 174
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 174
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 173
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 172
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 171
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 166
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 160
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 159
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 155
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 153
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 152
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 151
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 149
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 149
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 148
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 143
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 139
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 137
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 135
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 124
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 115
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 109
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 104
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 102
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 102
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 102
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 102
Management of Chronic Myeloid Leukemia in Advanced Phase 99
Second cancers in MPN: Survival analysis from an international study 76
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 73
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 73
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 71
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 67
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 66
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 65
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 65
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 63
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 62
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 53
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 49
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 29
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 1
Totale 6.569
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.816
article - articoli 18.293
book - libri 0
conference - conferenze 4.523
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202148 0 0 0 0 0 0 0 0 0 3 22 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/20251.078 46 57 39 187 60 39 83 76 137 67 97 190
2025/20263.153 217 188 206 542 838 192 287 179 306 198 0 0
Totale 6.569